On Wednesday 10th February we presented our story, a wart’s, and all Insights into a Pharma Start-Up: The Good, The Bad & The Ugly to students from the UCL Neuroscience Society and members of the public. TauRx is proud to be Gold sponsors of this important society, helping support the future generation of neuroscientists.
Attendance at the event was fantastic, as Professor Claude Wischik, CEO of TauRx, told the inspiring story of hope, compassion, hard work, determination, and belief as the foundational and continuous drivers of TauRx’ work as we strive to develop, a tau-focused, effective treatment for the world’s greatest unmet medical need, Alzheimer’s disease.
Professor Wischik took the audience back to the very beginnings of his Cambridge PhD days and his two key discoveries leading to the founding of TauRx in 2002. Revealing the challenges of going against dominant science by focusing on a tau-based treatment for over three decades, Claude explained how belief in our rigorous work and research findings mean that we must keep going with this focus. Commenting on the TauRx story so far, Claude offered several points of reflection for attendees, “If you are sure of your data, then have the courage to believe in what you find, even if this differs from mainstream opinion.”
This advice along with tales of the rocky, and at times jubilant path of truly thinking outside the box to secure funding as a small pharma start-up, was met with numerous comments and enthusiastic discussion from attendees who found it “fascinating” and “inspiring”.
TauRx is encouraged and delighted to have shared the ever-developing TauRx story and why the time for tau is now. We are grateful to the organising committee who “didn’t expect such a huge turn-out”, and to the attendees, we hope to present to you again, soon.
